Here's today's first piece on Investopedia. This was a stock (BDX) that I really wanted to cover when I was a sell-side analyst this last time around. Oh well ... water under the bridge.
http://stocks.investopedia.com/stock-analysis/2010/Becton-Dickinson-More-Interesting-Than-You-Think-BDX-CPHD-GPRO-LMNX-ABT-MDT-BAX-RHHBY-QGEN0503.aspx
For many years, Becton Dickinson (NYSE:BDX) has been summarily dismissed by a lot of portfolio managers as "too boring". Well, their loss. Although the stock of this diversified health care and biosciences company could not match the pace of health care all-star Medtronic (NYSE:MDT), it stacks up quite well against the likes of Abbott Labs (NYSE:ABT), Baxter (NYSE:BAX) and many other more "exciting" names. Proof, perhaps, that the steak is more satisfying than the sizzle.
A Quiet QuarterThe first quarter of 2010 was pretty much medium, with little to get excited about in either direction. Revenue growth of about 7% was in line with expectations, while the earnings per share (ex-items) were four cents ahead of the average estimate.
To read the full article, please click:
http://stocks.investopedia.com/stock-analysis/2010/Becton-Dickinson-More-Interesting-Than-You-Think-BDX-CPHD-GPRO-LMNX-ABT-MDT-BAX-RHHBY-QGEN0503.aspx
No comments:
Post a Comment